XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
  Arthritis
   Ankylosing Spondylitis
   Osteoarthritis
   Rheumatiod Arthritis
  Scleroderma
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Arthritis Channel
subscribe to Arthritis newsletter

Latest Research : Rheumatology : Arthritis

   DISCUSS   |   EMAIL   |   PRINT
Fighting inflammation with targeted liposomal therapy
Mar 29, 2006 - 1:08:00 PM, Reviewed by: Dr. Priya Saxena

RGD peptide liposomes delivering corticosteroids directly to inflamed sites indicate promise for the treatment of rheumatoid arthritis

 
Vascular endothelial cells (VECs) form the walls of blood vessels and play a critical role in inflammation. In rheumatoid arthritis (RA), VECs interact with cytokines, proteins that regulate immune response, and allow inflammation to persist, escalate, and progressively damage tissue, and joints. Recognized as potent inflammation inhibitors, corticosteroids work to control the expression of cytokines, adhesion molecules and the growth of endothelial cells. The potential of these drugs, however, has been restricted by their considerable toxicity and short half-life.

To study the impact of corticosteroids on VEC activity, researchers in The Netherlands turned to liposomes, microscopic vesicles used to deliver drugs or genetic material directly into a cell. They chose RGD peptide liposomes to deliver a dose of dexamethasone phosphate (DEXP) to VECs at the site of inflammation in rats with experimental arthritis. The results, presented in the April 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), indicate the promise of targeted liposomal therapy for rheumatoid arthritis patients.

RGD peptide was selected for targeting of the liposomes based on its high chemical stability and its high affinity for proteins expressed on angiogenic VECs At sties of inflammation. To create a disease sample, rats with adjuvant-induced arthritis (AIA) and rats or mice were injected with a lipopolysaccharide (LPS)-induced inflammation were used. After disease onset, generally 12 days after the inductions, the rats were randomly divided to receive treatment. One group received a single intravenous injection of 1 milligram of DEXP encapsulated in targeted RGD peptide-exposing polyethylene glycol liposomes (RGD-PEG-L). Another group was injected with the same dosage of DEXP encapsulated in non-targeted PEG liposomes. A control group was injected with an empty liposomes. To allow examination of liposome interactions with blood vessel walls in living animals, researchers used a mouse dorsal skin flap window model and distinguished RGD-PEG liposomes by fluorescent labels.

One hour after injection of the liposomes, which was performed only four hours after the induction of the inflammation, researchers observed strong binding of the RGD-PEG liposomes to the blood vessel wall at the site of the inflammation. Besides their rapid attack on VEC activity, the binding of RGD-PEG liposomes to inflamed sites was three-fold higher than that of the liposomes without the peptide.

Disease activity and its toll were monitored among the rats with AIA. Arthritis severity was scored by grading each paw from 0 to 4, based on redness, swelling, and joint immobility, with a maximum possible score of 16 per animal. Rats treated with DEXP-containing RGD-PEG liposomes showed the lowest overall scores, the strongest anti-inflammatory effects, and delayed disease progression.

This study demonstrates the potential of corticosteroid-carrying, VEC-binding RGD liposomes to quickly relieve inflammation and significantly reduce its ravages. "Using these liposomes to deliver DEXP to VECs at sites of arthritis involvement proved very efficacious in rat AIA, indicating promise for the treatment of rheumatoid arthritis," note the study's leading authors, Gert Storm, Ph.D. and Gerben Koning, Ph.D. "Future research will focus more precisely on the mechanisms involved and may also explore delivery of other anti-inflammatory compounds by the RGD-targeted liposomes."
 

- Article: "Targeting of Angiogenic Endothelial Cells at Sites of Inflammation by Dexamethasone Phosphate-Containing RGD Peptide Liposomes Inhibits Experimental Arthritis," Gerben A. Koning, Raymond M. Schiffelers, Marca H. M. Wauben, Robber J. Kok, Enrico Mastrobattista, Grietje Molema, Timo L. M. ten Hagen, and Gert Storm, Arthritis & Rheumatism, April 2006, 54:4, pp. 1198-1208.
 

www.interscience.wiley.com/journal/arthritis

 
Subscribe to Arthritis Newsletter
E-mail Address:

 



Related Arthritis News
DNA-covered submicroscopic bead used to deliver genes to treat rheumatoid arthritis
Rilonacept significantly reduced acute gout flares during uric acid-lowering therapy
Advances in genetics related to ankylosing spondylitis
Is Devil's Claw the key to treating arthritis?
High birth weight - risk for rheumatoid arthritis
Matrilin-3 gene discovered to prevent onset of osteoarthritis
Rituximab halts damage to joints
Tocilizumab effective in systemic juvenile idiopathic arthritis (sJIA)
Unfavourable blood fat levels predict rheumatoid arthritis up to 10 years later
Role of inflammatory leukocytes in extending tissue damage


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us